Oslo, Norway, 9 September 2025. EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, is pleased to announce that early, encouraging pre-clinical data on EXACT’s proprietary Acoustic Cluster Therapy (ACT®) in immune oncology will be presented at the upcoming Ninth International Cancer lmmunotherapy Conference (CICON25), during September 10-12, 2025, in Utrecht, The Netherlands.
The following two posters will be presented:
• Title: Acoustic Cluster Therapy (ACT) increases Anti-PD1 checkpoint inhibitor uptake in prostate
cancer in mice
• In collaboration with NTNU, the Norwegian University of Science and Technology
• Title: Evaluation of the immunostimulatory potential of Acoustic Cluster Therapy (ACT®) in melanoma
and breast cancer models in mice
• In collaboration with ICR, the Institute of Cancer Research, UK
The posters will be made available on the Company’s website.
About EXACT Therapeutics:
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the power of ultrasound and microbubbles to enable targeted drug delivery in oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be applied to a wide range of therapeutic agents within oncology and across a multitude of other indications, including brain diseases. EXACT Therapeutics’ shares are traded on Euronext Growth Oslo (EXTX). Further information may be found here: www.exact-tx.com
For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com